Seanc ,
You will likely still get your cocktail on Capri. $50 is not out of the question here. Markets love reliable forward earnings with strong growth potential. They’ll pay big multiples to get those earnings.
It won’t be too long before ACAD, announce further trials for FXS which is a much bigger market than RETTS. We have enough data now to give investors confidence that FXS is likely to come home just as well as the Retts trial.
Just the ROW deal should add Billion$ to the MC. Peak sales for RETTS alone should bring us over $350m per annum in earnings. At a PE of 20, that’s $6bn market cap or $30 per share.
If 2594 has any successful ph2 trials, we’ll then it really scales up from there.
NEU chart, page-69
-
- There are more pages in this discussion • 1,780 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
0.380(2.50%) |
Mkt cap ! $1.992B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $11.26M | 722.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 696 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.67 | 6942 | 8 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |